@anilkumar006

Epigenetics Market Is Expected to Witness a Steady Growth by 2026

2020-09-03T12:58:09.901Z

The Global Epigenetics market was valued at $630 million in 2017 and is expected to reach $1,321 million by 2023, registering a CAGR of 13.1% during the forecast period.

The surge in prevalence of cancer and other infectious diseases, increase in genome mapping programs worldwide, and advancements in gene technology drive the growth of the global epigenetics market. However, standardization concerns over epigenetic-based diagnostics and lack of skilled professionals in this field restrict market growth. Nonetheless, rise in awareness regarding epigenetics in emerging economies would create lucrative opportunities for new market players in the near future.

Request Sample Report at: https://www.alliedmarketresearch.com/request-sample/846

Instruments in epigenetics are projected to grow at the fastest rate

Based on product, the instruments segment is expected to grow at the fastest CAGR of 14.9% during the forecast period, supplemented by the increasing use of instruments in the analytical and life-science industry. However, the kits & assays segment occupied more than one-third of the global market in 2016 and is expected to continue its dominance throughout 2023.

Oncology to remain the dominant segment through 2023

By application, the oncology segment is expected to garner almost two-thirds of the global market from 2017 to 2023, owing to the growing trend of biomarker research and the rise in the development of anticancer therapies. However, the non-oncology segment is projected to grow at the fastest rate during the forecast period, owing to the effectiveness of epigenetic therapies in treating metabolic, inflammatory, and cardiovascular diseases.

Academic & government research institutes are expected to dominate the market

Based on end user, academic & government research institutes is anticipated to remain the dominant segment throughout the forecast period owing to rise in demand for extraction services, library preparation, methylation services, and clinical grade-targeted sequencing among researchers and scientists. However, the biotechnology companies segment is expected to grow at the fastest CAGR of 13.7% from 2017 to 2023.

For Purchase Enquiry: https://www.alliedmarketresearch.com/purchase-enquiry/846

Asia-Pacific to encounter the highest growth in the near future

As the markets in developed countries are almost saturated, Asia-Pacific is projected to provide major opportunities to venture capitalists and investors throughout the forecast period. The region is expected to grow at the highest CAGR of 14.8%, driven by significant developments by China and Japan towards incorporating new technologies in healthcare.

Key market players

The key players analyzed in the report include Abcam plc., Illumina, QIAGEN N.V., Merck & Co., New England Biolabs, Inc., Sigma-Aldrich Corporation, Thermo Fisher Scientific, Inc., Active Motif. Diagenode, Inc., and Zymo Research Corporation. They have adopted different strategies including collaborations, joint ventures, partnerships, expansions, mergers & acquisitions, and others to gain a strong position in the industry.

Oncology Information System Market Industry Analysis, Size, Share, Growth, Trends, and Forecast 2020 – 2026

2020-09-03T12:56:39.349Z

The report offers extensive analyses of the key winning strategies, industry dynamics, market size & forecast, and competitive landscape. As per the report, the global oncology information systems market was valued at $2.62 billion in 2017 and is estimated to reach $4.56 billion by 2025, registering a CAGR of 7.1% from 2018 to 2025.

Technological advancements in OIS, associated advantages of OIS over conventional record maintenance, and surge in prevalence of cancer worldwide drive the growth of the market. In addition, rise in awareness about the benefits of OIS is expected to supplement the market growth. However, high treatment costs associated with OIS and dearth of healthcare IT professionals hamper the market growth. On the other hand, integration of oncology information systems for the treatment of rare cancer types and increased usage of artificial intelligence (AI) in oncology information systems are expected to present new opportunities to market players in the future.

Request Sample Report at: https://www.alliedmarketresearch.com/request-sample/790

Software segment to be lucrative through 2025

Among product and services, the software segment contributed 81% share of total market revenue in 2017 and would retain its lead position through 2025. In addition, this segment is projected to grow at the fastest CAGR of 7.2% from 2018 to 2025 due to the higher adoption of oncology information system software among physicians to improve the management of patient information. The report also includes the analysis of the services segment.

Medical oncology segmentto lead in terms of revenueand growth rate

Among applications discussed in the study, the medical oncology segment accounted for 44% share of the total revenue in 2017 and would remain in its lead through 2025. Moreover, the segment would grow at the fastest CAGR of 7.7% during the forecast period because medical oncology information systems are extensively used to aid in the management, interpretation, analysis, and storage of patient information.

Hospitals and oncology clinics segment to dominate in terms of revenue

Among end users, the hospitals & oncology clinics segment accounted for 95% of the total market share in 2017 and would maintain its dominance through 2025. This is because most of the population prefer going to hospitals for treatment due to ease of access and host of treatment options under one roof. The oncology unit at elite hospitals are equipped with different oncology information systems that focus on improving efficiency and offering support-specific clinical and workflow needs of patients and clinicians, respectively. However, the research centers segment is projected to grow at the fastest CAGR of 9.2% during the study period, as scientists and researchers across the globe, especially in developed countries, have been conducting research on cancer due to its increased disease burden.

For Purchase Enquiry: https://www.alliedmarketresearch.com/purchase-enquiry/790

North America: highest revenue contributor through 2025

North America contributed about 35% of the total market share in 2017 and would continue to maintain its dominance by 2025 due to factors such as novel product launches, increased awareness of such systems, and favorable reimbursement scenario in the U.S. However, the Asia-Pacific region would register the highest CAGR of 7.6% from 2018 to 2025 due to rapidly changing healthcare infrastructure in the developing counties such as India, China and increasing awareness of the market among consumers and healthcare professionals. The other regions analyzed in the study include Europe and Latin America, Middle East and Africa (LAMEA).

Torchbearers of the industry

The key market players operating in the global oncology information systems market include Accuray Incorporated, Bogardus Medical Systems, Inc., Cerner Corporation, CureMD Corporation, Elekta AB, Flatiron Health, Inc., Koninklijke Philips N.V., McKesson Corporation, RaySearch Laboratories AB, and Varian Medical Systems, Inc. New product launches, joint ventures, expansions, mergers & acquisitions, partnerships, collaborations, and others are some of the strategies implemented by them to gain a stronghold in the industry.

Vertebral Compression Fracture Devices Market Capacity, Generation, Investment Trends, Regulations and Company Profiles report to 2026

2020-09-02T10:51:22.865Z

Global Vertebral compression fractures devices market was valued at $748 million in 2015, and is projected to reach $1,109 million by 2022, registering a CAGR of 5.7% from 2016 to 2022.

Vertebral compression fracture (VCF) generally occurs when the block-like part of a single bone of the spine (vertebra) is compressed due to trauma. The surgical approach for VCF treatment involves injecting cementing material in the fractured vertebra to provide immediate relief from pain and stability to the patient.

The vertebral compression fractures devices market is driven by factors such as advent of minimally invasive spine surgery techniques and rise in incidence of osteoporosis and arthritis. In addition, rise in geriatric population, short recovery period, low risk of infection, and shorter hospital stay are anticipated to boost the demand for VCF devices, globally. However, risk of post-surgical complications and stringent regulatory approval process hamper the market growth.

Download Free Sample Report @ https://www.alliedmarketresearch.com/request-sample/669

Balloon kyphoplasty devices segment is projected to maintain its leading trend in the global market, owing to the benefits offered by these procedures such as reduction of back pain and restoration of vertebral body height. Furthermore, vertebroplasty segment is anticipated to grow rapidly during the forecast period.

The global VCF devices market is segmented on the type of surgery into open spine surgery and minimally invasive spine surgery. The open spine surgery segment contributed the highest revenue in the global market in 2015. However, the MISS market is estimated to grow at the highest CAGR during the study period.

According to Deepa Tatkare, Senior Analyst, Healthcare Research, Allied Market Research, "The emergence of percutaneous vertebral augmentation procedures pose lucrative opportunities for key players in the VCF devices market. Percutaneous vertebral augmentation is preferred to other conventional techniques because of the associated benefits such as immediate, long-term pain relief and ideal treatment modality for osteoporotic VCF."

KEY FINDINGS OF VERTEBRAL COMPRESSION FRACTURES DEVICES MARKET :

The vertebroplasty devices segment is projected to grow at a CAGR of 6.1% during the forecast period.
The balloon kyphoplasty segment accounted for almost four-fifths share of the global vertebral compression fracture devices market in 2015.
Japan is the major shareholder in the Asia-Pacific VCF devices market, accounting for more than one-third share in 2015.
North America dominated the global market, accounting for two-thirds share in 2015.

Discount on Purchase @ https://www.alliedmarketresearch.com/purchase-enquiry/669

North America is expected to dominate the global market throughout the forecast period, owing to increased adoption of VCF devices in surgery, surge in procedure volumes caused by rapidly aging population, and rise in incidence of spinal disorders and impairments, such as spinal stenosis. However, Asia-Pacific region is projected to grow rapidly, registering a CAGR of 6.7% during the forecast period. Improving healthcare infrastructures and increase in expenditures in the emerging markets, such as India and China to cater to the unmet medical needs in these countries have bolstered the market growth.

The key players in the VCF devices market have focused on expanding their business operations in the fast-growing economies by adopting the product launch strategy. The major companies profiled in the report include Alphatec Holdings, Inc., Benvenue Medical, Depuy Synthes (Johnson & Johnson), Globus Medical, Inc., Medtronic plc, Orthovita, Inc., Osseon LLC, Stryker Corporation, VEXIM SA, and Zimmer Biomet Holdings, Inc.

Early Toxicity Testing Market Size by Key Companies, Trend, Size, Growth and Forecasts 2026

2020-09-02T10:48:19.881Z

Early toxicity testing Marketaccounted for $739 million in 2017 is expected to reach $1,301 million by 2025, registering a CAGR of 7.3% from 2018 to 2025.

Early toxicity testing is analysis of new molecular entity during development process to obtain data related to the toxic effects of compound on body. Testing is performed to analyze the different type of unwanted effects produced by the compound in the body. These severe adverse drug reactions in the body can be circumvented with the use of early toxicity testing which makes it an important part of preclinical testing. The testing is carried out in different mediums such as in vivo, in vitro, and in silico. These tests are carried out before clinical trials to analyze the drug candidates, which are further tested in clinical studies carried out in humans.

Download the Sample Report @ https://www.alliedmarketresearch.com/request-sample/619

Factors that drive the growth of the market include rise in R&D activities and surge in stringent regulatory authorities concerning public healthcare welfare. Increase in adoption of in vitro model which is the major current early toxicity testing market trend also boosts the growth of the market. However, challenges of preclinical testing hamper the market growth. Furthermore, technological advancements in preclinical diagnostic equipment provide lucrative opportunities for the early toxicity testing market growth.

Based on technique, the in vitro segment is a major revenue contributor in 2017 and is expected to maintain its dominant position throughout the analysis period due to rise in adoption of this technique across different diagnostic areas. Governments of different countries such as the U.S., the UK, Germany, and others are extensively active toward protection of animals. These countries have banned testing of cosmetic and household products on animals. Therefore, in vitro testing serves as a feasible alternative to in vivo testing, which also fuels the growth of the in vitro market. The in the silico segment is expected to be the fastest growing segment during the forecast period, owing to rise in its adoption due to advantages offered by the technique such as determination of metabolic pathways of active molecules.

According to end users, the pharmaceutical industry segment accounted for the highest early toxicity testing market share in 2017 and is anticipated to maintain this trend over the forecast period, owing to rise in number of clinical trials for drug development. Cosmetics industry segment is the fastest growing segment during the forecast period owing to the stringent government regulations monitoring the assessment of chemicals incorporated in cosmetic products.

Ask for Discount on Purchase @ https://www.alliedmarketresearch.com/purchase-enquiry/619

In 2017, Europe accounted for one-third of the total early toxicity testing market size and is expected to continue this trend owing to higher number of R&D activities, presence of research lab, companies and institutes, and wide availability of technologically advanced preclinical diagnostic instruments. On the other side, Asia-Pacific is estimated to register the fastest growth during the forecast period.

Key Findings of the Early Toxicity Testing Market:

Pharmaceutical industry occupied two-thirds share of the market in 2017.
The in the silico segment is anticipated to grow with the highest CAGR throughout the forecast period.
The in vitro segment accounted for half the share of the global early toxicity testing market in 2017.
The cosmetic segment is anticipated to grow at the highest rate during the analysis period.

The major companies profiled in this report include Agilent Technologies, Inc., General Electric Company (GE Healthcare), Danaher Corporation (Beckman Coulter, Inc.), Evotec AG (Cyprotex), Bioanalytical Systems, Inc., Bruker Corporation, Thermo Fisher Scientific, Inc., PerkinElmer Inc., Enzo Biochem, Inc. (Enzo Clinical Labs, Inc.), and Myriad Genetics, Inc. (Myriad RBM.).

Metabolomics Market 2020 Analyzed by Top 5 Key Players by Size, revenue and Forecasts To 2026

2020-08-19T10:29:14.773Z

Global Metabolomics market was valued at $1,572 million in 2017 and is expected to reach $3,301 Mn by 2023, growing at a CAGR of 13.2% during the forecast period.

The growth of the global metabolomics market is driven by rise in prevalence of chronic diseases worldwide, an upsurge in R&D investment for the development of metabolomics, and an increase in demand for personalized medicine. However, the lack of skilled professionals in the field along with the astronomical price of metabolomic instruments hampers market growth. Nonetheless, the immense potential of metabolomics in disease diagnostics and its growing prospect in human nutrition would create lucrative opportunities for emerging market players in the near future.

Request Sample Report at: https://www.alliedmarketresearch.com/request-sample/525

Metabolomics bioinformatics tools and services to hold a dominant position

Based on product & services, metabolomics bioinformatics tools and services segment is expected to be the largest and fastest growing segment through 2023. This is attributed to the tremendous progress demonstrated by bioinformatics, which is poised to grow even further in the near future driven by the use of robust algorithms and parameter estimation techniques in life-science research and analysis.

Cancer to remain the largest segment through 2023

By indication, the cancer segment is poised to occupy more than two-fifths of the global market by 2023, owing to the rise in the number of cancer incidences worldwide and the immense potential of discovering new cancer biomarkers through metabolomics research. However, other indicators segment is projected to grow at the fastest CAGR of 14.0%, as a wide range of fields including toxicology testing, finding nutrition levels, and drug discovery implement metabolomics as a diagnostic tool.

Personalized medicine to encounter the highest growth during the forecast period

By application, the personalized medicine segment is expected to exhibit the highest growth rate during the forecast period, a CAGR of 17.3%, due to its advantage over other segments in directly targeting the cause of any disease. However, the biomarker discovery segment is projected to generate almost half of the total revenue by 2023, driven by incessant research on finding biomarkers for cancer.

For Purchase Enquiry: https://www.alliedmarketresearch.com/purchase-enquiry/525

Asia-Pacific to grow at the fastest rate through 2023

Surge in cancer awareness, rise in medical tourism, and a large number of patient population that's estimated to increase are key factors that are projected to render Asia-Pacific the fastest growing region through 2023. However, Europe would continue to occupy the largest market share, owing to well-developed healthcare infrastructure and higher demand for metabolomics based diagnostics.

Key market players

The key players analyzed in the report include Agilent Technologies, Inc., Danaher Corporation, Biocrates Life Sciences AG, Bruker Corporation, Leco Corporation, Metabolon, Inc., Human Metabolome Technologies, Inc., Bio-Rad Laboratories, Inc., Shimadzu Corporation, Waters Corporation, and Thermo Fisher Scientific Inc. They have adopted different strategies including collaborations, joint ventures, partnerships, expansions, mergers & acquisitions, and others to gain a strong position in the industry.

Global Immunoprotein Diagnostic Testing Market Analysis Report 2020 by Size, Share, Growth and Assessment to 2026

2020-08-19T10:27:55.886Z

The report offers detailed analyses of the key winning strategies, market dynamics, market size & estimations, top investment pockets, and competitive landscape. As per the report, the global immunoprotein diagnostic testing market garnered $17.74 billion in 2017 and is expected to reach $27.29 billion by 2023, registering a CAGR of 7.4% from 2017 to 2023.

Rise in prevalence of cancer & cardiovascular diseases drive the growth of the immunoprotein diagnostic testing market. In addition, rise in healthcare expenditure and improvement in healthcare insurance scenario are expected to fuel the market growth during the study period. However, dearth of skilled healthcare professionals and lack of awareness among the population hamper the market growth.

Request Sample Report at: https://www.alliedmarketresearch.com/request-sample/486

Chemiluminescence assay segment to exhibit the fastest growth

The chemiluminescence assay (CLIA) segment is expected to register the fastest growth of 7.6% during the forecast period. This is because the adoption of CLIA would increase in future as this technology provides prompt and error-free results. However, the enzyme-based immunoassay (ELISA) segment captured the highest share of 30% in 2017 and would maintain its lion's share through 2023. The growth of the ELISA market is fueled by extensive use of immunoassays in cancer, POC IVD testing, infectious disease testing, therapeutic drug level monitoring alongside introduction of novel biomarkers. The report also analyzes radioimmunoassay, immunoturbidity assay, immunoprotein electrophoresis, immunofluorescence assay, and others segments.

Immunoglobulin diagnostic tests segment to be lucrative through 2023

Among types, the immunoglobulin diagnostic tests segment contributed the highest market share of 25% in 2017 and is expected to remain dominant throughout the forecast period. Moreover, the segment is expected to grow at the fastest CAGR of 8.0% from 2017 to 2023 due to the fact that immunoglobulin diagnostic tests are frequently used by healthcare professionals for diagnosing infectious or autoimmune disorders. The report also analyzes various types of tests such as C-reactive protein diagnostic tests, complement system protein diagnostic tests, prealbumin diagnostic tests, haptoglobin diagnostic tests, free light chain diagnostic tests, and others.

Infectious disease testing segment to lead in terms of revenue

Among applications, the infectious disease testing segment contributed 23% share of the total revenue in 2017, owing to high incidence of infectious diseases globally. However, the oncology testing segment would witness the fastest CAGR of 7.8% during the study period, owing to the significant rise in various types of cancer cases across the globe including, lung cancer, colorectal cancer, and others. The report also discusses autoimmune testing, allergy testing, endocrine testing, toxicology testing, among others.

For Purchase Enquiry: https://www.alliedmarketresearch.com/purchase-enquiry/486

North America to dominate, Asia-Pacific to be the fastest growing through 2023

North America accounted for 40% of the market share in 2017 and is expected to maintain its dominant position through the forecast period. This is attributed to the presence of leading diagnostic product manufacturers, higher adoption of advanced and efficient diagnostic products, heavy inflow of investment in proteomics research & drug development, and surge in the number of patients with viral infections and cancer in the region. On the other hand, Asia-Pacific is expected to grow at the fastest CAGR of 8.8% from 2017 to 2023, owing to factors such as higher adoption of point-of-care technology, rapidly growing geriatric population, and rise in incidence of chronic diseases in the region. The other regions discussed in the study are Europe, and Latin America, Middle East, and Africa (LAMEA).

Industry Frontrunners

The leading market players analyzed in the report include Abbott Laboratories, Abcam PLC, Bio-Rad Laboratories, Danaher Corporation, Diasorin, Enzo Life Sciences, Ortho Clinical Diagnostics, Roche Diagnostics, Siemens Healthcare, and Thermo Fisher Scientific. Various strategies such as expansions, joint ventures, mergers & acquisitions, collaborations, partnerships, and others have been implemented by these players to gain a stronghold in the industry.

Transdermal Drug Delivery Systems Market Research Report 2020 with Enormous Growth by Top Key Players

2020-08-18T13:11:08.487Z

Global Transdermal Drug delivery systems market was valued at $ 32,516 million in 2016, and is projected to reach $61,689 million by 2023, growing at a CAGR of 9.5% from 2017 to 2023. The passive system segment held more than three-fifths share of the total market in 2016.

Transdermal drug delivery systems are used to deliver drug through intact skin at a controlled rate into the systemic circulation. Increase in geriatric population and rise in number of patients suffering from chronic disorders, such as hypertension, diabetes, and angina, are expected to drive the market growth. Moreover, surge in adoption of new delivery system technologies, such as ultrasound, boosts the market growth. However, disadvantages of these delivery systems, such as irritation at the site of application and edema, are expected to impede the market growth.

Download the Sample Report @ https://www.alliedmarketresearch.com/request-sample/485

The passive system segment is expected to dominate the market throughout the analysis period, owing to increase in the incidence of chronic disorders, such as hypertension. The active system segment is expected to register highest CAGR of 12.8% during the forecast period.

Key Findings of the Transdermal Drug Delivery Systems Market:

· Reservoir system segment is projected to grow at a CAGR of 7.3% during the forecast period.

· Matrix system contributed for nearly two-third share of the global passive transdermal drug delivery systems market, in 2016.

· Structure-based drug delivery system segment is expected to register the highest CAGR of 13.3% during the analysis period.

· Cardiovascular disorders segment is expected to grow at the highest CAGR of 10.8% during the forecast period.

· France and Germany collectively contributed for more than one-third share of the European transdermal drug delivery systems market in 2016.

· Japan is the major shareholder, accounting for more than one-third share of the Asia-Pacific transdermal drug delivery systems market in 2016.

Ask for Discount on Purchase @ https://www.alliedmarketresearch.com/purchase-enquiry/485

Asia-Pacific is projected to register the highest CAGR of 10.1% during the forecast period, owing to improvement in healthcare infrastructures and rise in expenditures in emerging markets (India and China) to cater to the unmet medical needs. Technological advancements to develop cost-effective technologies in these nations offer a lucrative opportunity for the market growth.

The major companies profiled in the report includes Novartis AG, Johnson & Johnson, Mylan N.V., Boehringer Ingelheim GmbH, Bayer AG, Bristol-Myers Squibb Company, GlaxoSmithKline plc., Acrux Limited, Echo Therapeutics, Inc., and Endo Pharmaceuticals Inc.

Research focused on the Pharmacy Automation Systems Market forecast to 2026

2020-08-18T13:08:41.230Z

Pharmacy Automation Systems Market Report, published by Allied Market Research, forecasts that the global market was valued at $3,312 million in 2015, and is projected to reach $5,602 million by 2022, growing at a CAGR of 7.8% from 2016 to 2022.The automated medication dispensing systems held over half of the share of the global market in 2015.

Pharmacy automation systems manage dispensing, storing, filling, capping, and labeling of medications and securely store patient’s data. Constant technological developments, long-term cost savings associated with these systems, growth in adoption in emerging nations, rise in need to reduce medication errors, and increase in medical tourism in developing countries drive the growth of the market. However, high capital investment is projected to restrain the market growth during the forecast period.

Download the Sample Report @ https://www.alliedmarketresearch.com/request-sample/484

Detailed segmentation of the global pharmacy automation systems market is provided in terms of product type, end user, and geography. Based on product type, the market is divided into automated medication dispensing systems, automated storage & retrieval systems, automated packaging & labeling systems, tabletop tablet counters, and automated compounding devices. The automated medication dispensing segment held the largest share of 49.0% in 2015, owing to high these machines due to their point-of-care availability, capability to control storage & distribution, and maintain record of medicines.

By end user, the market is categorized into retail pharmacy, hospital pharmacy, and others (long-term care pharmacy, clinic pharmacy, and mail order pharmacy). Pharmacy automation systems held over half of the share in 2015 owing to major use in hospitals to package, dispense, and label medicines, and are expected to continue this trend in the future.

Key Findings of the Pharmacy Automation Systems Market

Automated medication dispensing systems was the leading segment in 2015.
North America is projected to grow at a CAGR of 7.5% from 2016 to 2022.
Asia-Pacific is expected to grow at the highest CAGR.
China is expected to grow at the highest CAGR in the Asia-Pacific pharmacy automation systems market.
France is expected to grow with the highest growth rate during the analysis period among the European countries.
Hospital held the largest market share o in 2015.

Ask for Discount on Purchase @ https://www.alliedmarketresearch.com/purchase-enquiry/484

Geographically, the market is analyzed across North America, Europe, Asia-Pacific, and LAMEA. North America generated the highest revenue, accounting for over half of the market share in 2015, owing to rise in expenditure to upgrade healthcare systems and high demand for technologically advanced devices for rapid & accurate distribution of medicines. However, Asia-Pacific is projected to grow at the highest CAGR during the analysis period, owing to rise in healthcare expenditure, increase in per capita income, and improvement in healthcare infrastructure.

The report provides a comprehensive analysis the key players operating in this market, including Baxter International Inc.; Becton, Dickinson and Company; Cerner Corporation; Capsa Healthcare; McKesson Corporation; Omnicell Inc.; ScriptPro LLC; Swisslog Holdings AG; Talyst, Inc.; and Yuyama Co., Ltd.

Dental Consumables Market Advanced Technologies & Growth Opportunities in Industry By 2026

2020-08-14T13:12:24.068Z

The report provides detailed analyses of the top winning strategies, market share & estimations, driving factors & opportunities, key market segments, and competitive landscape. As per the report, the global dental consumables market was pegged at $41.06 billion in 2017 and is expected to garner $55.58 billion by 2023, growing at a CAGR of 5.2% through 2023.

High prevalence of dental diseases among geriatric population, surge in dental tourism across emerging economies, and increase in demand for minimally invasive dental procedures drive the growth of the global dental consumables market. Moreover, increase in awareness about oral hygiene supplements the market growth. However, high cost of dental products along with very limited reimbursement hampers the growth of the market. On the contrary, rise in demand for dental cosmetic procedures and increase in awareness about proper dentition are expected to provide lucrative opportunities for the market players in the near future.

Request Sample Report at: https://www.alliedmarketresearch.com/request-sample/442

Retail dental care essentialssegment to retainlargest share through 2023

The retail dental care essentials segment held the largest share in 2017, contributing nearly two-thirds of the total market revenue. This is attributed to the surge in awareness programs for oral health & hygiene launched by major players & government organizations. However, the periodontics segment is projected to register the fastest CAGR of 12.2% during the forecast period, owing to rapid development of novel technologies and rise in incidence of periodontal diseases. The other segments analyzed in the report include dental implants, dental prosthetics, endodontics, and orthodontics.

Asia-Pacific region to manifest fastest growth by 2023

Asia-Pacific region is estimated to register the fastest CAGR of 7.6% through 2023, owing to rise in awareness regarding dental disorders, surge in geriatric population, improved accessibility to medical services, and increase in product availability. However, Europe held the largest market share in 2017, contributing more than one-third of the total revenue, owing to increase in the number of dental restoration cases due to high incidence of dental disorders in the region. The other regions analyzed in the report include North America and Latin America, Middle East and Africa (LAMEA).

For Purchase Enquiry: https://www.alliedmarketresearch.com/purchase-enquiry/442

Torchbearers of the market

The major market players analyzed in the report include 3M Company, Danaher Corporation, Institut Straumann AG, Koninklijke Philips N.V., Procter & Gamble, Colgate-Palmolive Company, Dentsply Sirona Inc., Ivoclar Vivadent, OSSTEM IMPLANT Co., Ltd., and Zimmer Biomet Holdings, Inc.

Arthroscopy Devices Market Analyzed Globally by Top key Industry Manufacturers and Assessment 2020 - 2026

2020-08-14T13:11:04.523Z

Arthroscopy Devices Market Report, published by Allied Market Research, forecasts that the global market was valued at $3,453 million in 2015 and is projected to reach $5,334 million by 2022, growing at a CAGR of 6.2% from 2016 to 2022. The arthroscopic implants segment held nearly two-fifths of the total market in 2015.

Arthroscopy is a minimally invasive surgical procedure that helps surgeons examine and treat bone and joint related problems using an arthroscope and other arthroscopy devices (such as visualization systems, arthroscopic implants, power shaver systems, radiofrequency devices, and others). They are essential to diagnose and treat osteoarthritis, rheumatoid arthritis, carpal tunnel syndrome, bone tumor, and others. The market for arthroscopy devices has grown tremendously in the recent years due to increase in number of sport injuries, rapid ageing population and increase in patient preference for minimally invasive surgeries.

Download Sample Report with Detailed COVID-19 Impact Analysis at: https://www.alliedmarketresearch.com/request-sample/426

Key factors that boost the growth of global arthroscopy devices market are the benefits of arthroscopy devices including shorter recovery time, minimal post-operative complications, and greater precision to perform surgeries of highly sensitive areas such as spine. In addition, upsurge in obesity rate causing bone degradation in population and the rise in demand for arthroscopic treatment in emerging economies offer lucrative opportunities for the growth of this market. However, dearth of skilled professionals and high costs associated with arthroscopic devices especially the novel implants (biodegradable and 3D implants) impede the market growth.

Arthroscopic implants are anticipated to dominate the arthroscopy devices market throughout the analysis period accounting for over two-fifths of the total share in 2015. This is owing to the rapid adoption attributed by the fact that implants mimic real joint-movement and are imperative in supporting damaged bone by facilitating faster joint recovery.

Visualization systems segment is expected to be the fastest growing sector of the market owing to the incorporation of advanced technologies in visualization systems, for instance, arthroscopic cameras embedded with ultra-high definition and 4-light emitting diode (LED) multi-light technology, which enhances the video quality. The global visualization system market is expected to grow at a CAGR of 8.2% from 2016 to 2022.

Spine arthroscopy dominated the application segment with about two-sevenths share in 2015 growing at a CAGR of 6.2% from 2016 to 2022. Growth in number of spine ailments such as degenerative conditions of the spine, spine trauma, tumors, spinal deformity, and infection of the spine amongst all age groups drives the market growth.

Discount on Purchase @ https://www.alliedmarketresearch.com/purchase-enquiry/426

Key findings of the Arthroscopy Devices Market:

The knee arthroscopy market is anticipated to witness the fastest growth rate during 20162022.
Visualization systems is projected to be the fastest growing segment during the analysis period.
Knee implants dominated the arthroscopic implants market, and is expected to grow at a CAGR of 5.2% during the forecast period.
North America dominated global arthroscopy devices market and is projected to grow at a CAGR of 5.4%.
Spine arthroscopy application occupied nearly two-sevenths of the total market in 2015.
India is the fastest growing country in Asia-Pacific region, registering a CAGR of 9.0% from 2016 to 2022.

In 2015, Asia-Pacific and LAMEA collectively accounted for one-fourth share of the total arthroscopy devices market and this trend is expected to continue due to rise in geriatric population & targeted diseases, specifically in China and India with large and other developing economies of the regions. Rise in sports as a career, surge in disposable income, improvement in healthcare funding, and high populace demanding more arthroscopic procedures fuel the growth of the arthroscopy devices market in the Asia-Pacific region.

The major companies profiled in the report include Arthrex, Inc. Conmed Corporation, Johnson & Johnson, KARL STORZ GmbH & Co. KG, Medtronic, Plc, Richard Wolf GmbH, Smith & Nephew, Plc, Stryker Corporation, Wright Medical Group N.V., and Zimmer Biomet Holdings, Inc.